34. Simpson SH et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus : a population- based cohort study. CMAJ 2006 Jan 17; 174: 169-174 35. Meinert CL et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortalità results. Diabetes 1970; 19 (Suppl): 789-830 36. Canadian Diabetes Association Clinical Practices Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27 (Suppl): S1-140. 37. The DREAM Trial Investigators. Effect of Ramipril on the Incidence of Diabetes. N Engl J Med. 2006 Oct 12; 355:1551-1562. 38. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 Sept 23; 368:1096-1105. 39. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 2006 Aug;29:1963-1972. 40. Ong CR et al. Long-Term Efficacy of Metformin Therapy in Nonobese Individuals With Type 2 Diabetes. Diabetes Care 2006 Nov; 29: 2361-2364 41. Nathan DM et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabees Care 2008 Jan; 31:173-175 42. Bayley CJ et al. Why is Exubera being withdrawn? BMJ 2007 Dec 1; 335:1156 43. Amori RE et al. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis. JAMA. 2007 Jul 11;298:194-206 44. American Diabetes Association. Clinical Practice Recommendations 2008. Diabetes Care 2008 Jan; Vol 31; Suppl. 1 45. http://www.pillole.org/public/aspnuke/news.asp?id=3795 46. http://www.pillole.org/public/aspnuke/news.asp?id=3796 47. Belch J et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840. 48. Nathan DM et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008 Dec. 31:1–11. 49. Selvin E et al. Cardiovascular Outcomes in Trials of Oral Diabetes Medications. A Systematic Review Arch Intern Med. 2008 Oct 27;168:2070-2080. 50. Ogawa H et al. for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes. A Randomized Controlled Trial. JAMA. 2008 Nov 12;300:2134-2141. 51. Holman RR et al. Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. N Engl J Med 2008 Oct 9; 359: 1565-1576 52. Holman RR et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008 Oct 9; 359:1577-1589. 53. Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. U.S. Preventive Services Task Force. Ann Intern Med 2009 Mar 17; 150: 396-404 54. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 2009 May 30; 373:1849-1860 55. De Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials. BMJ 2009; DOI:10.1136/bmj.b4531.
|
|
